ERBB2 and breast cancer: Dr Sara Hurvitz from the University of California, Los Angeles, CA and colleagues discussed the results of the BOLERO-1 trial, a phase III double blind, placebo-controlled multicentre trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER-2+ advanced breast cancer.